BIO-Europe EBD Group BIO BIO-Europe
Email this page Share this on LinkedIn Share this on Twitter

BIO-Europe® 2014 Press Releases

November 17, 201420th Annual BIO-Europe® 2014 partnering meetings outnumber all previous yearsSuccess of industry event confirms valued role of partnering in bringing drugs to patients
The 20th anniversary edition of BIO-Europe® international partnering conference wrapped up last week, November 3–5, in Frankfurt, Germany, at the Portalhaus Messe Frankfurt conference center. The conference attracted over 3,200 leading dealmakers from 54 countries comprising 1,786 companies made up of biotech, large and midsize pharma, and finance along with emerging com...  more ►

October 16, 2014BIO-Europe® 2014 Program is abundant showcase of life science pharma executives and thought leaders BIO-Europe® 2014 international partnering conference will take place, November 3–5 in Frankfurt, Germany, at the Portalhaus Messe Frankfurt conference center. BIO-Europe is Europe's largest partnering conference serving the global biotechnology industry. The conference annually attracts leading dealmakers from biotech, pharma and finance along with the most exciting emerging...  more ►

October 8, 2014BIO-Europe® 2014 partnering meetings expected to surpass all previous events The BIO-Europe® 2014 international partnering conference will take place in one month on November 3–5 in Frankfurt, Germany, at the Portalhaus Messe Frankfurt. BIO-Europe is the largest dedicated partnering conference worldwide serving the life science industry. The 2014 Frankfurt event projects the number of one-to-one partnering meetings to surpass the 2013 all-time rec...  more ►

August 12, 2014BIO-Europe® 2014 kicks off its 20th year as life science partnering leader
Event will be held in Frankfurt, Germany this year
The twentieth annual BIO-Europe® international partnering conference will take place November 3–5 in Frankfurt, Germany, at the Portalhaus Messe Frankfurt conference center. "BIO-Europe has continued to be the leading European life science partnering event because of the high caliber companies that bring their teams to partner," said Florian Schoenhammer, Managing Direct...  more ►

August 1, 2014Spotlight on Frankfurt Business Facts The state of Hessen has top ranked cities: Frankfurt, Wiesbaden and Kassel are among the top 10 cities in Germany (based on WiWo City Ranking 2012). Frankfurt is Germany's major airport and leading hub in Europe with over 57.5 million passengers per year and 4,575 direct flight connections per week. Overall, 108 airlines fly to 295 destinations in 105 countries. There are tw...  more ►

partnering360® Blog

December 17, 2014 Key incentives for doing business in China: Interview with Dan Zhang of Fountain Medical Development Ltd. You hear it a lot: China is the next big thing for life science companies, and any company interested in establishing a presence in China would be tapping into a lucrative, growing market. And it’s true: China is now the world’s second largest healthcare market and is on track to be the largest... more ►

December 11, 2014 Cancer immunotherapies and nano-based delivery approaches sure to be hot topics in 2015 A recent article published in the November 26, 2014 issue of Frontiers In Chemistry magazine discussed the performance and toxicity of various cancer immunotherapies, specifically monoclonal antibodies, immune adjuvants, vaccines and cell-based treatments, their differing delivery methods, and the... more ►

December 8, 2014 Partnerships are powerful in moving from apps to medical devices According to PricewaterhouseCooper, one of the top trends to keep an eye on next year in the healthcare field is the evolving role of medical apps moving to medical devices.  Next year, the FDA is set to review hundreds of apps.  But PWC points out that even though they’ve been reviewing... more ►

December 2, 2014 The complexity of immuno-oncology trials The value of developing an immunotherapy has grown over the past few years – as science and technology has developed far enough to help the immune system better recognize cancer cells as an abnormality within the human body.  The potential of this cancer treatment is huge as it would allow... more ►

December 1, 2014 More good news for private biotechs Guest post by Sara Jane Demy, CEO, Demy-Colton Life Science Advisors Polaris Partners joins the parade of new biotech funds launched in 2014 with a USD 450 million fund which exceeds the USD 400 million number they filed with the SEC last summer. Polaris joins Arch, Venrock, Versant and Sofinnova,... more ►

partnering360:Insight Latest headlines from partnering360:Insight

December 9, 2014 Interview with Dan Zhang, Foundation Medical Development partneringNEWS recently spoke with Dan Zhang, CEO of Fountain Medical Development, a CRO based mainly in China, but also with offices in the US, Taiwan, Hong Kong and South Korea. With China being the second largest healthcare market in the world, Zhang talks about the incentives for global companies to do business in China, and the ways in which FMD facilitates that. more ►

November 11, 2014 Bayer committed to Open Innovation and Collaborators The Head of Global Drug Discovery at Bayer HealthCare and a Member of the Executive Committee, Andreas Busch described the strategy underlying partnering efforts that he said have delivered a very significant value to patients as well as to shareholders. more ►

November 11, 2014 Merck Serono embraces partnering in all its forms Executive VP and Head of Global Research and Development at Merck Serono, Luciano Rossetti is also a Member of the Executive Committee who joined the company in late July this year. He offered to share with the audience a perspective from what he called a brief tenure. more ►

November 11, 2014 European biotech poised for acceleration David Loew is Senior VP for Commercial Operations in Europe at Sanofi. Rather than focusing on the company, Loew turned the spotlight on a wider concern for promoting a stronger environment for biotechs and start-ups in Europe. more ►

November 11, 2014 Transformational deals that shaped the industry in 2014 Led by moderator David Stubbs, the Managing Director for Inverness Advisors, the goal for the panel was to provide insights for transformational deals of the past year. The session was led off by a truly transformational deal that saw the USD 14.2 billion divestiture by Merck of its consumer healthcare business to Bayer HealthCare in May, 2014. The deal makes Bayer the second-biggest over-the-counter drug maker behind Johnson & Johnson. more ►

Arrow Up

See more upcoming conferences ►

EBD Group's Family of Events

© 2009–2014 EBD GmbH
Privacy Policy
Terms of Use
BIO-Europe EBD Group BIO BIO-Europe